Citations

Citations to this article as recorded by  

• A Case of Insulinoma with Hyperprocalcitoninemia and Hypercalcitoninemia Showing Coexpression of Insulin and Calcitonin in Its Tumor Cells
  Tomoko Kaketaka, Ikuo Mineo, Yu Kimura, Naohiko Ito, Yukiyoshi Okauchi, Hiromi Tamura, Shiro Adachi, Hiromi Iwahashi
  Internal Medicine.2024;[Epub]     CrossRef
• [111In]In-CP04 as a novel cholecystokinin-2 receptor ligand with theranostic potential in patients with progressive or metastatic medullary thyroid cancer: final results of a GRAN-T-MTC Phase I clinical trial
  Luka Lezaic, Paola Anna Erba, Clemens Decristoforo, Katja Zaletel, Renata Mikolajczak, Helmut Maecke, Theodosia Maina, Mark Konijnenberg, Petra Kolenc, Malgorzata Trofimiuk-Müldner, Elwira Przybylik-Mazurek, Irene Virgolini, Marion de Jong, Alide C Fröber
  European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(3): 892.     CrossRef
• Diagnostic tests for medullary thyroid carcinoma: an umbrella review
  Pierpaolo Trimboli, Caterina Mian, Arnoldo Piccardo, Giorgio Treglia
  Endocrine.2023; 81(2): 183.     CrossRef
• Advances in Diagnostics and Therapy of Medullary Thyroid Carcinoma (MTC)– A Mini-Review
  Michał Miciak, Krzysztof Jurkiewicz
  Clinical Cancer Investigation Journal.2023; 12(5): 1.     CrossRef
• Role of Polypeptide Inflammatory Biomarkers in the Diagnosis and Monitoring of COVID-19
  Aparajita Sen, Arti Nigam, Meenakshi Vachher
  International Journal of Peptide Research and Therapeutics.2022;[Epub]     CrossRef
• A pregnancy-specific reference interval for procalcitonin
  Samuel Dockree, Jennifer Brook, Tim James, Brian Shine, Manu Vatish
  Clinica Chimica Acta.2021; 513: 13.     CrossRef
• Clinical performance of calcitonin and procalcitonin Elecsys® immunoassays in patients with medullary thyroid carcinoma
  Luca Giovanella, Martina Fontana, Franco Keller, Frederik A. Verburg, Luca Ceriani
  Clinical Chemistry and Laboratory Medicine (CCLM).2021; 59(4): 743.     CrossRef
• Correlation between preoperative ultrasonic features of medullary thyroid carcinoma and postoperative recurrence
  Qiaodan Zhu, Dong Xu
  BMC Cancer.2021;[Epub]     CrossRef
• Calcitonin and complementary biomarkers in the diagnosis of hereditary medullary thyroid carcinoma in children and adolescents
  Felix Eckelt, Roland Pfaeffle, Wieland Kiess, Juergen Kratzsch
  Journal of Pediatric Endocrinology and Metabolism.2021; 34(12): 1491.     CrossRef
• Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis
  Marisa A. Bartz-Kurycki, Omowunmi E. Oluwo, Lilah F. Morris-Wiseman
  Therapeutic Advances in Endocrinology and Metabolism.2021; 12: 204201882110496.     CrossRef
• Diagnostic Challenges of Medullary Thyroid Carcinoma
  Robert D. Leimbach, Thanh D. Hoang, Mohamed K.M. Shakir
  Oncology.2021; 99(7): 422.     CrossRef
• The Diagnostic and Antibiotic Reference Values of Procalcitonin for Intracranial Infection After Craniotomy
  Lei Zhu, Lun Dong, Yuping Li, Guangyu Lu, Hengzhu Zhang, Xingdong Wang, Xiaoguang Liu, Zhenfei Teng, Boming Xia, Peng Zhang
  World Neurosurgery.2019; 126: e1.     CrossRef
• Triennial Report ofEndocrinology and Metabolism, 2015 to 2017
  Eun-Jung Rhee, Hey Yeon Jang, Won-Young Lee
  Endocrinology and Metabolism.2018; 33(2): 195.     CrossRef

Medullary thyroid carcinoma (MTC) is a rare neuroendocrine tumor derived from the thyroid C cells producing calcitonin. MTC accounts for 0.6% of all thyroid cancers and incidence of MTC increased steadily between 1997 and 2011 in Korea. It occurs either sporadically or in a hereditary form based on germline rearranged during transfection (RET) mutations. MTC can be cured only by complete resection of the thyroid tumor and any loco-regional metastases. The most appropriate treatment is still less clear in patients with residual or recurrent disease after initial surgery or those with distant metastases because most patients even with metastatic disease have indolent courses with slow progression for several years and MTC is not responsive to either radioactive iodine therapy or thyroid-stimulating hormone suppression. Recently, two tyrosine kinase inhibitors (TKIs), vandetanib and cabozantinib, are approved for use in patients with advanced, metastatic or progressive MTC. In this review, we summarize the current approach according to revised American Thyroid Association guidelines and recent advances in systemic treatment such as TKIs for patients with persistent or recurrent MTC after surgery.

Citations

Citations to this article as recorded by  

• [68Ga]Ga-DOTA-FAPI-04 PET/CT depicts metastases from medullary thyroid cancer that [68Ga]Ga-DOTATOC PET/CT missed
  Akram Al-Ibraheem, Salem Fandi Alyasjeen, Ahmed Saad Abdlkadir, Areej Abu Sheikha
  European Journal of Nuclear Medicine and Molecular Imaging.2023; 50(13): 4112.     CrossRef
• Molecular Mechanism and Clinical Application of Thyroid Cancer
  ·如孜 卡地力艳
  Advances in Clinical Medicine.2023; 13(12): 20543.     CrossRef
• Research Progress of the Molecular Mechanism of Antithyroid Cancer Activity of Shikonin
  Chunguang Sun, Lin Liao
  Current Molecular Pharmacology.2023;[Epub]     CrossRef
• Multiple endocrine neoplasia 2: an overview
  B Saravana-Bawan, JD Pasternak
  Therapeutic Advances in Chronic Disease.2022; 13: 204062232210792.     CrossRef
• Total thyroidectomy vs thyroid lobectomy for localized medullary thyroid cancer in adults: A propensity-matched survival analysis
  Weili Liang, Jinyuan Shi, Hui Zhang, Guixu Lv, Tiantian Wang, Yong Wang, Bin Lv, Luchuan Li, Qingdong Zeng, Lei Sheng
  Surgery.2022; 172(5): 1385.     CrossRef
• Naphthoquinones and derivatives as potential anticancer agents: An updated review
  Md Mominur Rahman, Md Rezaul Islam, Shopnil Akash, Sheikh Shohag, Limon Ahmed, Fatema Akter Supti, Abdur Rauf, Abdullah S.M. Aljohani, Waleed Al Abdulmonem, Anees Ahmed Khalil, Rohit Sharma, Muthu Thiruvengadam
  Chemico-Biological Interactions.2022; 368: 110198.     CrossRef
• Metformin Decreases Serum Thyroglobulin Concentration in Nonmedullary Thyroid Carcinoma
  Celina Caetano, Paola Tabaro Pico, Charan Singh, Beatriz Tendler, Diana M Malchoff, Carl D Malchoff
  Journal of the Endocrine Society.2022;[Epub]     CrossRef
• Long non-coding RNA LINC00488 facilitates thyroid cancer cell progression through miR-376a-3p/PON2
  Fuyuan Xie, Longgen Li, Yuting Luo, Rensheng Chen, Jinhong Mei
  Bioscience Reports.2021;[Epub]     CrossRef
• Decision Making When Cancer Becomes Chronic: Needs Assessment for a Web-Based Medullary Thyroid Carcinoma Patient Decision Aid
  Danielle Shojaie, Aubri S Hoffman, Ruth Amaku, Maria E Cabanillas, Julie Ann Sosa, Steven G Waguespack, Mark E Zafereo, Mimi I Hu, Elizabeth E Grubbs
  JMIR Formative Research.2021; 5(7): e27484.     CrossRef
• Long Non-coding RNA RUNDC3A-AS1 Promotes Lung Metastasis of Thyroid Cancer via Targeting the miR-182-5p/ADAM9
  Dawei Ma, Yan Zhu, Xiao Zhang, Jia Zhang, Wei Chen, Xinyuan Chen, Yichun Qian, Yanbin Zhao, Tingting Hu, Zhangyu Yao, Wei Zhao, Yuan Zhang, Fangzhou Liu
  Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
• Effects of marital status on survival of medullary thyroid cancer stratified by age
  Lei Ai, Ning Li, Hai‐Long Tan, Bo Wei, Ya‐Xin Zhao, Pei Chen, Hui‐Yu Hu, Mian Liu, Deng‐Jie Ou‐Yang, Zi‐en Qin, Peng Huang, Shi Chang
  Cancer Medicine.2021; 10(24): 8829.     CrossRef
• The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study
  Tal Rozenblat, Dania Hirsch, Eyal Robenshtok, Simona Grozinsky-Glasberg, David J. Gross, Haggi Mazeh, Carlos Benbassat, Orit Twito, Sigal Levy, Aviram Mizrachi, Thomas Shpitzer, Gideon Bachar
  European Journal of Surgical Oncology.2020; 46(11): 2023.     CrossRef

• Multiple Auer Rods in Fine-Needle Aspiration Smears of Medullary Thyroid Carcinoma: An Unusual Finding

  
  Maryam Mohammadnia Avval, Perikala Vijayananda Kumar, Fereydoon Dehghani
  International Medical Case Reports Journal.2020; Volume 13: 85.     CrossRef
• Lymph Node Metastases of Medullary Thyroid Cancer: Role of Calcitonin in the Washout Fluid of Fine-Needle Aspiration
  Bernardo Marques, Nuno Cunha, Raquel G. Martins, Ana Rita Elvas, Joana Couto, Jacinta Santos, Teresa Martins, Ana Paula Moniz, Olga Ilhéu, Frederico Valido, Fernando Rodrigues
  International Journal of Endocrinology.2020; 2020: 1.     CrossRef
• Efficacy and Safety of Vandetanib in Progressive and Symptomatic Medullary Thyroid Cancer: Post Hoc Analysis From the ZETA Trial
  Michael C. Kreissl, Lars Bastholt, Rossella Elisei, Robert Haddad, Ole Hauch, Barbara Jarząb, Bruce Robinson, Raffaella Colzani, Meredith Foster, Richard Weiss, Martin Schlumberger
  Journal of Clinical Oncology.2020; 38(24): 2773.     CrossRef
• Medullary thyroid cancer: epidemiological pattern and factors contributing to recurrence and metastasis
  O Hamdy, S Awny, IH Metwally
  The Annals of The Royal College of Surgeons of England.2020; 102(7): 499.     CrossRef
• Carcinoma medular de tiroides estadio iv y gestación
  B. Sánchez Lechuga, C. López Tinoco, I. Gavilán Villarejo, F.J. Vílchez López, M. Aguilar Diosdado
  Clínica e Investigación en Ginecología y Obstetricia.2019; 46(1): 35.     CrossRef
• Bildgebung beim medullären Schilddrüsenkarzinom
  M. Uhrig, S. Delorme
  Der Radiologe.2019; 59(11): 992.     CrossRef
• Recent Development of Nuclear Molecular Imaging in Thyroid Cancer
  Huiting Liu, Xiaoqin Wang, Ran Yang, Wenbing Zeng, Dong Peng, Jason Li, Hu Wang
  BioMed Research International.2018; 2018: 1.     CrossRef
• Radioguided hepatic resection with l -DOPA in metastatic medullary thyroid carcinoma
  Javier López-Gómez, Sevastian Medina-Ornelas, Ma. Alejandra Salazar-Álvarez, Mario Álvarez-Bojórquez, Noel Zaragoza-Cruz, Javier Melchor-Ruan, Alethia Álvarez-Cano
  Revista Española de Medicina Nuclear e Imagen Molecular (English Edition).2018; 37(4): 244.     CrossRef
• EF24 (a Curcumin Analog) and ZSTK474 Emphasize the Effect of Cabozantinib in Medullary Thyroid Cancer
  Loris Bertazza, Francesca Sensi, Elisabetta Cavedon, Sara Watutantrige-Fernando, Simona Censi, Jacopo Manso, Federica Vianello, Eric Casal Ide, Maurizio Iacobone, Raffaele Pezzani, Caterina Mian, Susi Barollo
  Endocrinology.2018; 159(6): 2348.     CrossRef
• Resección hepática radioguiada con 18 F-DOPA en un paciente con carcinoma medular de tiroides metastásico
  J. López-Gómez, S. Medina-Ornelas, M.A. Salazar-Álvarez, M. Álvarez-Bojórquez, N. Zaragoza-Cruz, J. Melchor-Ruan, A. Álvarez-Cano
  Revista Española de Medicina Nuclear e Imagen Molecular.2018; 37(4): 244.     CrossRef
• Genotypic characteristics and their association with phenotypic characteristics of hereditary medullary thyroid carcinoma in Korea
  Kyong Yeun Jung, Seok-Mo Kim, Min Joo Kim, Sun Wook Cho, Bup-Woo Kim, Yong Sang Lee, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Kyu Eun Lee, Eun-Jae Chung, Hyo Jeong Kim, Do Joon Park, Myung-Whun Sung, Cheong Soo Park, Bo Youn Cho, Young Joo Park, Han
  Surgery.2018; 164(2): 312.     CrossRef
• Thyroid cancer management
  Francesco Perri, Antonio Giordano, Salvatore Pisconti, Franco Ionna, Maria G. Chiofalo, Francesco Longo, Davide Leopardo, Giuseppina Della Vittoria Scarpati, Luciano Pezzullo
  Anti-Cancer Drugs.2018; 29(6): 483.     CrossRef
• Clinicopathological Significance and Prognosis of Medullary Thyroid Microcarcinoma: A Meta‐analysis
  Jin Hwa Kim, Jung‐Soo Pyo, Won Jin Cho
  World Journal of Surgery.2017; 41(10): 2551.     CrossRef
• A label-free electrochemical immunosensor based on gold nanoparticles and graphene oxide for the detection of tumor marker calcitonin
  Nawal A. Alarfaj, Maha F. El-Tohamy
  New Journal of Chemistry.2017; 41(19): 11029.     CrossRef
• Evaluation of in vitro and in vivo activity of a multityrosine kinase inhibitor, AL3810, against human thyroid cancer
  Qin Xie, Hui Chen, Jing Ai, Ying-lei Gao, Mei-yu Geng, Jian Ding, Yi Chen
  Acta Pharmacologica Sinica.2017; 38(11): 1533.     CrossRef
• Articles inEndocrinology and Metabolismin 2016
  Won-Young Lee
  Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef